Literature DB >> 32914822

How Parkinson's disease-related mutations disrupt the dimerization of WD40 domain in LRRK2: a comparative molecular dynamics simulation study.

Xinyi Li1, Mingyu Ye1, Yue Wang1, Ming Qiu1, Tingting Fu1, Jian Zhang1, Bin Zhou2, Shaoyong Lu1.   

Abstract

The multidomain kinase enzyme leucine-rich-repeat kinase 2 (LRRK2), activated through a homodimerization manner, has been identified as an important pathogenic factor in Parkinson's disease (PD), the second most common neurodegenerative disease wordwide. The Trp-Asp-40 (WD40) domain, located in the C-terminal LRRK2, harbours one of the most frequent PD-related variants, G2385R. However, the detailed dynamics of WD40 during LRRK2 dimerization and the underlying mechanism through which the pathogenic mutations disrupt the formation of the WD40 dimer have remained elusive. Here, microsecond-scale molecular dynamics simulations were employed to provide a mechanistic view underlying the WD40 dimerization and unveil the structural basis by which the interface-based mutations G2385R, H2391D and R2394E compromise the corresponding process. The simulation results identified important residues, D2351, R2394, E2395, R2413, and R2443, involved in establishing the complex binding network along the dimerization interface, which was significantly weakened in the presence of interfacial mutations. A "sag-bulge" model was proposed to explain the unfavorable dimer formation in the mutant systems. In addition, mutations altered the community configuration in the wild-type system in which inter-monomeric interplay is prominent, leading to the destabilization of the WD40 dimer under mutation.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32914822     DOI: 10.1039/d0cp03171b

Source DB:  PubMed          Journal:  Phys Chem Chem Phys        ISSN: 1463-9076            Impact factor:   3.676


  7 in total

1.  Deciphering the selective binding mechanisms of anaplastic lymphoma kinase-derived neuroblastoma tumor neoepitopes to human leukocyte antigen.

Authors:  Wenchao Tian; Xianxian Liu; Lulu Wang; Bufeng Zheng; Kun Jiang; Guoyong Fu; Wenyu Feng
Journal:  J Mol Model       Date:  2021-04-26       Impact factor: 1.810

2.  Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy.

Authors:  Shibo Zhou; Bo Yang; Yufeng Xu; Aihua Gu; Juan Peng; Jinfeng Fu
Journal:  J Mol Model       Date:  2022-08-06       Impact factor: 2.172

3.  Insights into the Allosteric Effect of SENP1 Q597A Mutation on the Hydrolytic Reaction of SUMO1 via an Integrated Computational Study.

Authors:  Mingfei Ji; Zongtao Chai; Jie Chen; Gang Li; Qiang Li; Miao Li; Yelei Ding; Shaoyong Lu; Guanqun Ju; Jianquan Hou
Journal:  Molecules       Date:  2022-06-28       Impact factor: 4.927

4.  Understanding the P-Loop Conformation in the Determination of Inhibitor Selectivity Toward the Hepatocellular Carcinoma-Associated Dark Kinase STK17B.

Authors:  Chang Liu; Zhizhen Li; Zonghan Liu; Shiye Yang; Qing Wang; Zongtao Chai
Journal:  Front Mol Biosci       Date:  2022-05-10

5.  Conformational Selection Mechanism Provides Structural Insights into the Optimization of APC-Asef Inhibitors.

Authors:  Xinheng He; Ning Huang; Yuran Qiu; Jian Zhang; Yaqin Liu; Xiao-Lan Yin; Shaoyong Lu
Journal:  Molecules       Date:  2021-02-11       Impact factor: 4.411

6.  Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase.

Authors:  Shuai Liang; Qing Wang; Xuesen Qi; Yudi Liu; Guozhen Li; Shaoyong Lu; Linkai Mou; Xiangyu Chen
Journal:  Front Cell Dev Biol       Date:  2021-12-23

7.  Mechanistic Insights into the Mechanism of Inhibitor Selectivity toward the Dark Kinase STK17B against Its High Homology STK17A.

Authors:  Chang Liu; Yichi Zhang; Yuqing Zhang; Zonghan Liu; Feifei Mao; Zongtao Chai
Journal:  Molecules       Date:  2022-07-21       Impact factor: 4.927

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.